Compound semaglutide first week: what the science says

What's this video probably claiming?

First-week semaglutide content on TikTok follows a pretty predictable script. The creator is almost certainly documenting early side effects, appetite changes, and maybe some scale movement. These videos typically involve claims like "I'm not hungry at all," "I lost X pounds already," or "this stuff is wild." There's probably some excited commentary about how fast it works, and almost certainly zero mention of the fact that week one is the lowest titration dose, meaning the effects being shown are not representative of what happens at therapeutic doses. Compound semaglutide adds another layer: the creator may be implying, intentionally or not, that their compounded version is functionally identical to Wegovy or Ozempic. That's a claim worth scrutinizing carefully.

What does the science actually show?

The STEP 1 trial (Wilding et al., 2021, NEJM) established that semaglutide 2.4mg weekly produces roughly 14.9% mean body weight reduction over 68 weeks in adults with obesity. That's the headline number people cite. What gets buried is the titration schedule: patients start at 0.25mg weekly and don't hit the full 2.4mg dose until week 17. The weight loss seen in week one is largely water weight and reduced caloric intake from nausea, not the drug's full pharmacological effect on GLP-1 receptors. The drug's half-life is approximately seven days, so steady-state plasma concentrations aren't even reached until four to five weeks in. Early dramatic results shared on social media almost always reflect the honeymoon phase, not the clinical trajectory.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok semaglutide content and clinical reality is timeline compression. Creators document week one like it's a product review, when the actual therapeutic arc plays out over months. A second major divergence is around compound versus brand-name semaglutide. The FDA has been explicit: compounded semaglutide is not the same as FDA-approved Ozempic or Wegovy. The active ingredient may be semaglutide base or semaglutide sodium rather than the specific formulation that was tested in trials. Potency, sterility, and bioavailability are not guaranteed to match. The FDA placed semaglutide on the shortage list, which allowed compounding pharmacies to legally produce it, but that status has been revised and the regulatory picture is shifting. Creators almost never address this distinction, and their audiences almost never ask.

What should you actually know?

If you're watching this video to decide whether compound semaglutide is worth trying, the week-one content is essentially useless as a decision-making tool. What actually matters: whether the pharmacy is 503A or 503B accredited, whether you have documented clinical oversight, and whether your dose is being titrated by someone tracking your response, not a protocol you found on Reddit. The STEP trials used specific injectable formulations with defined pharmacokinetics. Any compounded version sits outside that evidence base, full stop. That doesn't mean compounded semaglutide has no effect, but it means you cannot assume trial-level efficacy or the same side-effect profile. Nausea, vomiting, and gastroparesis risk are real and dose-dependent. Early enthusiasm from week one rarely survives the four-to-six month mark without structured clinical support.